期刊
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
卷 84, 期 -, 页码 289-298出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neubiorev.2017.08.018
关键词
Depression; Depressive disorder; Aging; Geriatrics; Nicotine; Nicotinic receptor; Cognition; Cognitive impairment; Acetylcholine; Antidepressant; Review; Attention; Memory; Default mode network; Intrinsic network; Cognitive control; Executive control; Experimental therapeutics
资金
- NIH [K24 MH110598]
- CTSA from the National Center for Advancing Translational Sciences [UL1TR000445]
Late-life depression is characterized by both lower mood and poor cognitive performance, symptoms that often do not fully respond to current antidepressant medications. Nicotinic acetylcholine receptor (nAChR) agonists such as nicotine may serve as a novel therapeutic approach for this population. Both preclinical and preliminary clinical studies suggest that nAChR agonists can improve depressive behavior in animal models and improve mood in depressed individuals. Substantial literature also supports that nAChR agonists benefit cognitive performance, particularly in older populations. These potential benefits may be mediated by the effects of nAChR stimulation on neural network function and connectivity. Functional neuroimaging studies detail effects of nAChR agonists on the default mode network, central-executive network, and salience network that may oppose or reverse network changes seen in depression. We propose that, given the existent literature and the clinical presentation of late-life depression, nicotine or other nAChR agonists may have unique therapeutic benefits in this population and that clinical trials examining nicotine effects on mood, cognition, and network dynamics in late-life depression are justified.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据